Miglustat hydrochloride
Based on 7 publication(s) in Google Scholar
Miglustat (N-Butyldeoxynojirimycin) hydrochloride is an orally active and reversible ceramide glucosyltransferase inhibitor, with blood-brain barrier permeability. Miglustat hydrochloride can be used for the research of type I gaucher disease.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit : 99.97%
- CAS. Nr.: 210110-90-0
- Formel: C10H22ClNO4
- Molecular Weight:255.74
-
Speicherung:
-20°C, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
-
Lösungsmittel & Löslichkeit
- Protokoll
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
-
HY-16743
IbiglustatGlucosylceramide Synthase Inhibitor -
HY-106392
LucerastatGlucosylceramide Synthase Inhibitor -
HY-14885A
Eliglustat hemitartrateGlucocerebroside Synthase Inhibitor -
HY-14885
EliglustatGlucocerebroside Synthase Inhibitor -
HY-100944
Conduritol B epoxideGcase Inhibitor -
HY-17502
SimvastatinHMGCR Inhibitor -
HY-10181
DasatinibSrc/Bcr-Abl Inhibitor -
HY-15760
Necrostatin-1RIPK1 Inhibitor -
HY-117383
NGI-1Virus Protease Inhibitor -
HY-112879
Mito-TEMPOAntioxidant -
HY-106443A
Arimoclomol maleateHSP Co-Inducer -
HY-16134A
Celgosivir hydrochlorideα-Glucosidase I Inhibitor
Publications Citing Use of MedChemExpress (MCE) Miglustat hydrochloride
More- Cell. 2019 Dec 12;179(7):1483-1498.e22. [Abstract]
- Nat Commun. 2024 Aug 14;15(1):6970. [Abstract]
- Cell Rep. 2022 Jul 5;40(1):111049. [Abstract]
- Front Pharmacol. 2023 Jun 26:14:1191692. [Abstract]
- J Virol. 2026 Apr 21;100(4):e0027026. [Abstract]
- J Virol. 2025 Mar 18;99(3):e0001825. [Abstract]
- Preprints. 2023 Dec 20.
Customer Validation & Images
-
Cell Proliferation/Viability Assay
-
RT-PCR
-
WB
-
Cell Imaging/Staining
-
In Vivo Imaging
Biologische Aktivität
Beschreibung
In Vitro
Miglustat (200 μM; 2, 4 and 24 h) hydrochloride restores F508del-CFTR (cystic fibrosis transmembrane conductance regulator) function in cystic fibrosis (CF) bronchial epithelial IB3-1 and CuFi-1 cells. Miglustat hydrochloride reduces the inflammatory response to P. aeruginosa in both CF and non-CF bronchial cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:NPC1−/− mice[1]
-
Dosage:0.2 mg/kg
-
Administration:Oral administration; once
-
Result:Was able to rescue synaptic plasticity deficits, to restore ERKs activation and to counteract hyperexcitability.
Chemical Information
-
CAS. Nr. 210110-90-0
-
Appearance Solid
-
Molecular Weight 255.74
-
Formel C10H22ClNO4
-
Color White to light brown
-
SMILES
O[C@H]1[C@H](O)[C@@H](CO)N(CCCC)C[C@@H]1O.[H]Cl
-
Synonyms
N-Butyldeoxynojirimycin hydrochloride; NB-DNJ hydrochloride; OGT 918 hydrochloride
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
-20°C, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)
Publications (7)
-
Journal Impact Factor
-
Most Recent
-
Cell
2019 Dec 12;179(7):1483-1498.e22. PMID: 31813625 -
Nat Commun
Inhibition of glycosphingolipid synthesis with eliglustat in combination with immune checkpoint inhibitors in advanced cancers: preclinical evidence and phase I clinical trial. [Abstract]2024 Aug 14;15(1):6970. PMID: 39138212
Miglustat hydrochloride purchased from MedChemExpress. Usage Cited in: Nat Commun. 2024 Aug 14;15(1):6970. [Abstract]
Miglustat combined with anti-PD-1 promotes tumour inhibition. MC38-OVA cells (1 × 105 328 ) were subcutaneously injected into C57BL/6 mice treated with PBS, Miglustat alone (10 mg/kg), anti-PD-1 antibody alone (200 mg/kg per mouse) or Miglustat plus anti-PD-1 as indicated and tumour formation was observed. Tumour sizes were measured every 3 days. The average and individual tumour curves are shown.
-
Cell Rep
The perinuclear theca protein Calicin helps shape the sperm head and maintain the nuclear structure in mice. [Abstract]2022 Jul 5;40(1):111049. PMID: 35793634
Miglustat hydrochloride purchased from MedChemExpress. Usage Cited in: Cell Rep. 2022 Jul 5;40(1):111049. [Abstract]
Ccin-EGFP-KI male mice were fed by 15 mg/kg Miglustat (NB-DNJ) per day for 5 weeks. NB-DNJ is a drug to disrupt the fusion of the small proacrosomal vesicles into a single acrosome. PNA-FITC-labeled acrosome and EGFP signals were almost lost after NB-DNJ treatment.
Miglustat hydrochloride purchased from MedChemExpress. Usage Cited in: Cell Rep. 2022 Jul 5;40(1):111049. [Abstract]
Ccin-EGFP-KI male mice were fed by 15 mg/kg Miglustat (NB-DNJ) per day for 5 weeks, the shape of sperm from Ccin-eGFP-KI mice was obviously changed and the acrosome was absent.
Miglustat hydrochloride purchased from MedChemExpress. Usage Cited in: Cell Rep. 2022 Jul 5;40(1):111049. [Abstract]
Ccin-EGFP-KI male mice were fed by 15 mg/kg Miglustat (NB-DNJ) per day for 5 weeks, The protein levels of Zpbp1 (an acrosomal marker) and eGFP-tagged calicin were significantly reduced.
-
Front Pharmacol
HECT, UBA and WWE domain containing 1 represses cholesterol efflux during CD4+ T cell activation in Sjögren's syndrome. [Abstract]2023 Jun 26:14:1191692. PMID: 37435494 -
J Virol
Disruption of spike protein N-glycosylation induces its endoplasmic reticulum retention and attenuates SARS-CoV-2 infectivity. [Abstract]2026 Apr 21;100(4):e0027026. PMID: 41910405 -
J Virol
STT3B promotes porcine epidemic diarrhea virus replication by regulating N-glycosylation of PEDV S protein. [Abstract]2025 Mar 18;99(3):e0001825. PMID: 39945486
Miglustat hydrochloride purchased from MedChemExpress. Usage Cited in: J Virol. 2025 Mar 18;99(3):e0001825. [Abstract]
Miglustat (5, 10 μM; 24 h) showed no cytotoxicity for Vero cells.
Miglustat hydrochloride purchased from MedChemExpress. Usage Cited in: J Virol. 2025 Mar 18;99(3):e0001825. [Abstract]
Miglustat (5, 10 μM) decreased the PEDV N mRNA levels in a dose-dependent manner in Vero cells.
Miglustat hydrochloride purchased from MedChemExpress. Usage Cited in: J Virol. 2025 Mar 18;99(3):e0001825. [Abstract]
Miglustat (5, 10 μM) decreased the PEDV N prodein levels in a dose-dependent manner in Vero cells.
Miglustat hydrochloride purchased from MedChemExpress. Usage Cited in: J Virol. 2025 Mar 18;99(3):e0001825. [Abstract]
Immunofluorescence assay (IFA) images of Vero cells infected with PEDV and treated with indicated Miglustat (5, 10 μM). Viral N-protein is shown in green, and the nuclei are blue.
-
Lösungsmittel & Löslichkeit
In Vitro:
DMSO : 65 mg/mL (254.16 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : ≥ 34 mg/mL (132.95 mM)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 3.25 mg/mL (12.71 mM); Clear solution
This protocol yields a clear solution of ≥ 3.25 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (32.5 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 3.25 mg/mL (12.71 mM); Clear solution
This protocol yields a clear solution of ≥ 3.25 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (32.5 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: PBS
Solubility: 100 mg/mL (391.02 mM); Clear solution; Need ultrasonic
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Working solution concentration: 0.22 mg/mL
This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
Protokoll
-
Transepithelial/transendothelial electrical resistance assay
TEER measures electrical resistance across epithelial or endothelial monolayers cultured on permeable supports, and the readout reflects ionic conductance through the cell barrier, especially the paracellular pathway regulated by junctional integrity. TEER can be measured without destroying the monolayer and is commonly used before or during transport, permeability, barrier-disruption, and barrier-maturation experiments. TEER values are influenced by biological maturation and technical conditions; reported factors include temperature, medium formulation, passage number, electrode geometry, membrane properties, and junctional length during early monolayer maturation. Therefore, TEER should be interpreted with blank-insert subtraction, area normalization, repeated readings, and, when possible, orthogonal barrier readouts such as FITC-dextran flux or tight-junction staining.
Reinheit & Dokumentation
-
Data Sheet (277 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
Verweise
[1]. Maria Cristina Dechecchi, et al. Anti-inflammatory effect of miglustat in bronchial epithelial cells. J Cyst Fibros. 2008 Nov;7(6):555-65. [Content Brief]
[2]. G D'Arcangelo, et al. Miglustat Reverts the Impairment of Synaptic Plasticity in a Mouse Model of NPC Disease. Neural Plast. 2016:2016:3830424. [Content Brief]
[3]. Patterson MC, et al. Miglustat for treatment of Niemann-Pick C disease: a randomised controlled study. Lancet Neurol. 2007 Sep;6(9):765-72. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O / DMSO | 1 mM | 3.9102 mL | 19.5511 mL | 39.1022 mL | 97.7555 mL |
| 5 mM | 0.7820 mL | 3.9102 mL | 7.8204 mL | 19.5511 mL | |
| 10 mM | 0.3910 mL | 1.9551 mL | 3.9102 mL | 9.7756 mL | |
| 15 mM | 0.2607 mL | 1.3034 mL | 2.6068 mL | 6.5170 mL | |
| 20 mM | 0.1955 mL | 0.9776 mL | 1.9551 mL | 4.8878 mL | |
| 25 mM | 0.1564 mL | 0.7820 mL | 1.5641 mL | 3.9102 mL | |
| 30 mM | 0.1303 mL | 0.6517 mL | 1.3034 mL | 3.2585 mL | |
| 40 mM | 0.0978 mL | 0.4888 mL | 0.9776 mL | 2.4439 mL | |
| 50 mM | 0.0782 mL | 0.3910 mL | 0.7820 mL | 1.9551 mL | |
| 60 mM | 0.0652 mL | 0.3259 mL | 0.6517 mL | 1.6293 mL | |
| 80 mM | 0.0489 mL | 0.2444 mL | 0.4888 mL | 1.2219 mL | |
| 100 mM | 0.0391 mL | 0.1955 mL | 0.3910 mL | 0.9776 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Miglustat hydrochloride Related Classifications
HY-17020A Related Classifications
Powered by Bioz